FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Isakson

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Anatomy

B-Lymphocytes

Co-author Network

Publications

TOP 3
James K Gierse; Yan Zhang; William F Hood; Mark Crossfield Walker; Jennifer S Trigg; Timothy J Maziasz; Carol M Koboldt; Jerry L Muhammad; Ben S Zweifel; Jaime L Masferrer; Peter C Isakson; Karen Seibert
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Pär Gyllfors; Grazyna Bochenek; John Overholt; Diane Drupka; Maria Kumlin; James R Sheller; Ewa Nizankowska; Peter C Isakson; Filip Mejza; James B Lefkowith; Sven-Erik Dahlén; Andrew Szczeklik; John Joseph Murray; Barbro Dahlén
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
William F Hood; James K Gierse; Peter C Isakson; James R Kiefer; Ravi Kurumbail; Karen Seibert; Joseph B Monahan
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Isakson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: James K Gierse; Yan Zhang; William F Hood; Mark Crossfield Walker; Jennifer S Trigg; Timothy J Maziasz; Carol M Koboldt; Jerry L Muhammad; Ben S Zweifel; Jaime L Masferrer; Peter C Isakson; Karen Seibert
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1206-12.
2003: Pär Gyllfors; Grazyna Bochenek; John Overholt; Diane Drupka; Maria Kumlin; James R Sheller; Ewa Nizankowska; Peter C Isakson; Filip Mejza; James B Lefkowith; Sven-Erik Dahlén; Andrew Szczeklik; John Joseph Murray; Barbro Dahlén
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
The Journal of allergy and clinical immunology 2003;111(5):1116-21.
2003: William F Hood; James K Gierse; Peter C Isakson; James R Kiefer; Ravi Kurumbail; Karen Seibert; Joseph B Monahan
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
Molecular pharmacology 2003;63(4):870-7.
2003: Peter C Isakson
Pharmacology of COX-2 inhibitors.
Progress in experimental tumor research 2003;37():25-51.
2003: Svetlana Vidensky; Yan Zhang; Tracey Hand; Joe Goellner; Alex Shaffer; Peter C Isakson; Katrin Andreasson
Neuronal overexpression of COX-2 results in dominant production of PGE2 and altered fever response.
Neuromolecular medicine 2003;3(1):15-28.
2002: Paola Ciceri; Yan Zhang; Alex F Shaffer; Kathleen M Leahy; Mark B Woerner; Walter G Smith; Karen Seibert; Peter C Isakson
Pharmacology of celecoxib in rat brain after kainate administration.
The Journal of pharmacology and experimental therapeutics 2002;302(3):846-52.
2002: James K Gierse; Ravi Kurumbail; Mark Walker; Bill Hood; Joseph B Monahan; Jennifer Pawlitz; Rick Stegeman; Anna Stevens; Jim Kiefer; Carol M Koboldt; Kirby Moreland; Scott W Rowlinson; Lawrence J Marnett; Jennifer Pierce; Jeff Carter; John J Talley; Peter C Isakson; Karen Seibert
Mechanism of inhibition of novel COX-2 inhibitors.
Advances in experimental medicine and biology 2002;507():365-9.
2002: Alane T Koki; Nasir K Khan; B Mark Woerner; Andrew J Dannenberg; Lisa Olson; Karen Seibert; Dorothy Edwards; Madorra Hardy; Peter C Isakson; Jaime L Masferrer
Cyclooxygenase-2 in human pathological disease.
Advances in experimental medicine and biology 2002;507():177-84.
2001: Katrin Andreasson; Alena V Savonenko; Svetlana Vidensky; J J Goellner; Y Zhang; Alex Shaffer; Walter E Kaufmann; Paul F Worley; Peter C Isakson; Alicja L Markowska
Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(20):8198-209.
2001: Mark Crossfield Walker; Ravi Kurumbail; James R Kiefer; Kirby Moreland; Carol M Koboldt; Peter C Isakson; Karen Seibert; James K Gierse
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
The Biochemical journal 2001;357(Pt 3):709-18.
2001: Kenneth M Verburg; Timothy J Maziasz; E Weiner; L Loose; G Steven Geis; Peter C Isakson
Cox-2-specific inhibitors: definition of a new therapeutic concept.
American journal of therapeutics 2001;8(1):49-64.
2000: IK Khanna; Y Yu; R M Huff; Richard M Weier; X Xu; Francis J Koszyk; PW Collins; JN Cogburn; Peter C Isakson; Carol M Koboldt; Jaime L Masferrer; WE Perkins; Karen Seibert; AW Veenhuizen; J Yuan; D C Yang; YY Zhang
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
Journal of medicinal chemistry 2000;43(16):3168-85.
2000: Andrew Whelton; G Schulman; Carl B Wallemark; E J Drower; Peter C Isakson; Kenneth M Verburg; G Steven Geis
Effects of celecoxib and naproxen on renal function in the elderly.
Archives of internal medicine 2000;160(10):1465-70.
2000: P T Leese; Richard C Hubbard; A Karim; Peter C Isakson; S S Yu; G Steven Geis
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.
Journal of clinical pharmacology 2000;40(2):124-32.
1999: Paul Emery; H Zeidler; T K Kvien; M Guslandi; R Naudin; H Stead; Kenneth M Verburg; Peter C Isakson; Richard C Hubbard; G Steven Geis
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
Lancet 1999;354(9196):2106-11.
1999: Lee S Simon; A L Weaver; D Y Graham; Alan J Kivitz; P E Lipsky; Richard C Hubbard; Peter C Isakson; Kenneth M Verburg; SS Yu; William W Zhao; G Steven Geis
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
JAMA : the journal of the American Medical Association 1999;282(20):1921-8.
1999: WG Bensen; J J Fiechtner; J I McMillen; William W Zhao; SS Yu; E M Woods; Richard C Hubbard; Peter C Isakson; Kenneth M Verburg; G Steven Geis
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Mayo Clinic proceedings. Mayo Clinic 1999;74(11):1095-105.
1999: Karen Seibert; J Lefkowith; Catherine S Tripp; Peter C Isakson; P Needleman
COX-2 inhibitors--is there cause for concern?
Nature medicine 1999;5(6):621-2.
1999: James K Gierse; Carol M Koboldt; Mark Crossfield Walker; Karen Seibert; Peter C Isakson
Kinetic basis for selective inhibition of cyclo-oxygenases.
The Biochemical journal 1999;339 ( Pt 3)():607-14.
1999: A Margalit; S D Hauser; Peter C Isakson
Regulation of in vivo prostaglandin biosynthesis by glutathione.
Advances in experimental medicine and biology 1999;469():165-8.
1998: C J Smith; Yan Zhang; Carol M Koboldt; J Muhammad; Ben S Zweifel; Alex F Shaffer; John J Talley; Jaime L Masferrer; Karen Seibert; Peter C Isakson
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(22):13313-8.
1998: Lee S Simon; F L Lanza; P E Lipsky; Richard C Hubbard; Sheela Talwalker; B D Schwartz; Peter C Isakson; G Steven Geis
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Arthritis and rheumatism 1998;41(9):1591-602.
1998: A Margalit; S D Hauser; Ben S Zweifel; M A Anderson; Peter C Isakson
Regulation of prostaglandin biosynthesis in vivo by glutathione.
The American journal of physiology 1998;274(2 Pt 2):R294-302.
1998: C M Venturini; Peter C Isakson; P Needleman
Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms.
Current opinion in nephrology and hypertension 1998;7(1):79-82.
1997: Yan Zhang; Alex F Shaffer; J Portanova; Karen Seibert; Peter C Isakson
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production.
The Journal of pharmacology and experimental therapeutics 1997;283(3):1069-75.
1997: Walter E Kaufmann; Katrin Andreasson; Peter C Isakson; Paul F Worley
Cyclooxygenases and the central nervous system.
Prostaglandins 1997;54(3):601-24.
1997: P Needleman; Peter C Isakson
The discovery and function of COX-2.
The Journal of rheumatology. Supplement 1997;49():6-8.
1997: IK Khanna; Richard M Weier; Y Yu; X D Xu; Francis J Koszyk; PW Collins; Carol M Koboldt; AW Veenhuizen; WE Perkins; J J Casler; Jaime L Masferrer; YY Zhang; S A Gregory; Karen Seibert; Peter C Isakson
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.
Journal of medicinal chemistry 1997;40(11):1634-47.
1997: IK Khanna; Richard M Weier; Y Yu; PW Collins; Julie M Miyashiro; Carol M Koboldt; AW Veenhuizen; J L Currie; Karen Seibert; Peter C Isakson
1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2.
Journal of medicinal chemistry 1997;40(11):1619-33.
1997: Thomas D Penning; John J Talley; SR Bertenshaw; JS Carter; PW Collins; Stephen H Docter; Matthew J Graneto; L F Lee; James W Malecha; Julie M Miyashiro; R S Rogers; DJ Rogier; Stella S Yu; Earl G Burton; JN Cogburn; S A Gregory; Carol M Koboldt; WE Perkins; Karen Seibert; AW Veenhuizen; YY Zhang; Peter C Isakson
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Journal of medicinal chemistry 1997;40(9):1347-65.
1997: A Margalit; K L Duffin; Alex F Shaffer; S A Gregory; Peter C Isakson
Altered arachidonic acid metabolism in urate crystal induced inflammation.
Inflammation 1997;21(2):205-22.
1997: Karen Seibert; Yan Zhang; Kathleen M Leahy; S Hauser; Jaime L Masferrer; Peter C Isakson
Distribution of COX-1 and COX-2 in normal and inflamed tissues.
Advances in experimental medicine and biology 1997;400A():167-70.
1997: Walter E Kaufmann; Paul F Worley; CV Taylor; M Bremer; Peter C Isakson
Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome.
Brain & development 1997;19(1):25-34.
1996: Jason D. Weber; Peter C Isakson; J M Purkerson
IL-5 receptor expression and Ig secretion from murine B lymphocytes requires coordinated signaling by membrane Ig, IL-4, and IL-5.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(10):4428-35.
1996: J P Portanova; Yan Zhang; G D Anderson; S D Hauser; Jaime L Masferrer; Karen Seibert; S A Gregory; Peter C Isakson
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.
The Journal of experimental medicine 1996;184(3):883-91.
1996: G D Anderson; S D Hauser; K L McGarity; M E Bremer; Peter C Isakson; S A Gregory
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
The Journal of clinical investigation 1996;97(11):2672-9.
1996: J J Li; M B Norton; E J Reinhard; G D Anderson; S A Gregory; Peter C Isakson; Carol M Koboldt; Jaime L Masferrer; WE Perkins; Karen Seibert; Yan Zhang; Ben S Zweifel; D B Reitz
Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
Journal of medicinal chemistry 1996;39(9):1846-56.
1996: Walter E Kaufmann; Paul F Worley; J Pegg; M Bremer; Peter C Isakson
COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(6):2317-21.
1996: A Margalit; K L Duffin; Peter C Isakson
Rapid quantitation of a large scope of eicosanoids in two models of inflammation: development of an electrospray and tandem mass spectrometry method and application to biological studies.
Analytical biochemistry 1996;235(1):73-81.
1996: H C Huang; J J Li; D J Garland; T S Chamberlain; E J Reinhard; R E Manning; Karen Seibert; Carol M Koboldt; S A Gregory; G D Anderson; AW Veenhuizen; Yan Zhang; WE Perkins; Earl G Burton; J N Cogburn; Peter C Isakson; D B Reitz
Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships.
Journal of medicinal chemistry 1996;39(1):253-66.
1995: W G Smith; Alex F Shaffer; J L Currie; J M Thompson; S Kim; T Rao; Peter C Isakson
Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
The Journal of pharmacology and experimental therapeutics 1995;275(3):1332-8.
1995: S J Mnich; AW Veenhuizen; J B Monahan; K C Sheehan; K R Lynch; Peter C Isakson; J P Portanova
Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(9):4437-44.
1995: J J Li; G D Anderson; Earl G Burton; J N Cogburn; J T Collins; D J Garland; S A Gregory; H C Huang; Peter C Isakson; Carol M Koboldt
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
Journal of medicinal chemistry 1995;38(22):4570-8.
1995: R Huff; P Collins; S Kramer; Karen Seibert; Carol M Koboldt; S Gregory; Peter C Isakson
A structural feature of N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs its selectivity and affinity for cyclooxygenase 2 (COX2).
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1995;44 Suppl 2():S145-6.
1995: D J Fretland; C P Anglin; M Bremer; Peter C Isakson; Deborah L Widomski; S K Paulson; S H Docter; S W Djuric; T D Penning; S Yu
Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: impact upon leukotriene B4- and 12(R)-HETE-mediated events.
Inflammation 1995;19(2):193-205.
1995: James K Gierse; S D Hauser; D P Creely; Carol M Koboldt; S H Rangwala; Peter C Isakson; Karen Seibert
Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.
The Biochemical journal 1995;305 ( Pt 2)():479-84.
1995: Peter C Isakson; Karen Seibert; Jaime L Masferrer; Daniela Salvemini; L Lee; P Needleman
Discovery of a better aspirin.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():49-54.
1995: D J Welsch; D P Creely; K J Mathis; S D Hauser; Peter C Isakson
Molecular cloning and expression of human leukotriene C4 synthase.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():167-9.
1995: Karen Seibert; Jaime L Masferrer; Y Zhang; S Gregory; G Olson; S Hauser; K Leahy; W Perkins; Peter C Isakson
Mediation of inflammation by cyclooxygenase-2.
Agents and actions. Supplements 1995;46():41-50.
1994: Karen Seibert; Y Zhang; K Leahy; S Hauser; Jaime L Masferrer; W Perkins; L Lee; Peter C Isakson
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12013-7.
1994: Peter C Isakson; S Hauser; Y Zhang; K Leahy; Jaime L Masferrer; Karen Seibert
Cytokine regulation of eicosanoid generation.
Annals of the New York Academy of Sciences 1994;744():181-3.
1994: D J Welsch; D P Creely; S D Hauser; K J Mathis; G G Krivi; Peter C Isakson
Molecular cloning and expression of human leukotriene-C4 synthase.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(21):9745-9.
1994: T S Rao; SS Yu; S W Djuric; Peter C Isakson
Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor.
Journal of lipid mediators and cell signalling 1994;10(3):213-28.
1994: J M Purkerson; Peter C Isakson
Independent regulation of DNA recombination and immunoglobulin (Ig) secretion during isotype switching to IgG1 and IgE.
The Journal of experimental medicine 1994;179(6):1877-83.
1994: T S Rao; J L Currie; Alex F Shaffer; Peter C Isakson
In vivo characterization of zymosan-induced mouse peritoneal inflammation.
The Journal of pharmacology and experimental therapeutics 1994;269(3):917-25.
1994: Jaime L Masferrer; Ben S Zweifel; Pamela T Manning; S D Hauser; K M Leahy; W G Smith; Peter C Isakson; Karen Seibert
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(8):3228-32.
1994: T S Rao; Alex F Shaffer; J L Currie; Peter C Isakson
Role of mast cells in calcium ionophore (A23187)-induced peritoneal inflammation in mice.
Inflammation 1994;18(2):187-92.
1993: T S Rao; J L Currie; Alex F Shaffer; Peter C Isakson
Comparative evaluation of arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation.
Inflammation 1993;17(6):723-41.
1993: T S Rao; J L Currie; Alex F Shaffer; Peter C Isakson
Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat.
Life sciences 1993;53(9):PL147-52.
1992: J Purkerson; Peter C Isakson
A two-signal model for regulation of immunoglobulin isotype switching.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1992;6(14):3245-52.
1992: J M Purkerson; Peter C Isakson
Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE.
The Journal of experimental medicine 1992;175(4):973-82.
1992: K M Catron; J M Purkerson; Peter C Isakson; T P Bender
Constitutive versus cell cycle regulation of c-myb mRNA expression correlates with developmental stages in murine B lymphoid tumors.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(3):934-42.
1991: Peter C Isakson; J Purkerson; K Catron; T P Bender
A novel method for synchronizing a B cell lymphoma.
Journal of immunological methods 1991;145(1-2):137-42.
1991: J M Purkerson; Peter C Isakson
Isotype switching in anti-immunoglobulin-activated B lymphoblasts: differential requirements for interleukin 4 and other lymphokines to elicit membrane vs. secreted IgG1.
European journal of immunology 1991;21(3):707-14.
1990: K M Catron; C R Toth; J Purkerson; Peter C Isakson; T P Bender
Constitutive and cell cycle regulated expression of c-myc mRNA is related to the state of differentiation in murine B-lymphoid tumors.
Current topics in microbiology and immunology 1990;166():197-202.
1989: Peter C Isakson; D D'Angelo; J Schetz; L Tardelli; Ellen Puré
Anti-Ig-stimulated B lymphoblasts can be restimulated via their surface Ig.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(12):3901-8.
1989: L Simpson; Ian K McNiece; M Newberg; J Schetz; Kevin R Lynch; P Quesenberry; Peter C Isakson
Detection and characterization of a B cell stimulatory factor (BSF-TC) derived from a bone marrow stromal cell line.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(11):3894-900.
1988: J M Purkerson; M Newberg; G Wise; Kevin R Lynch; Peter C Isakson
Interleukin 5 and interleukin 2 cooperate with interleukin 4 to induce IgG1 secretion from anti-Ig-treated B cells.
The Journal of experimental medicine 1988;168(3):1175-80.